By staff writers

September 20, 2019 -- Biopharmaceutical company Affibody and GE Healthcare are collaborating to develop and bring to market Affibody's PET imaging tracers.

The company's ABY-025 is a HER2-detecting PET imaging tracer under clinical development, Affibody said. It is for use in diagnosing metastatic breast cancer, according to the firm.

Affibody is also developing PD-L1, a binding molecule that would be used to improve selection and monitoring of patients with immuno-oncology treatments, and will work with GE on clinical proof-of-concept studies.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking